DK2086940T3 - Fumaratsalt af (alfa- s, beta-r)-6-brom-alfa-[2-(dimethylamino)-ethyl]-2-methoxy-alfa-1-naphthalenyl-beta-phenyl-3-quinolinethanol - Google Patents

Fumaratsalt af (alfa- s, beta-r)-6-brom-alfa-[2-(dimethylamino)-ethyl]-2-methoxy-alfa-1-naphthalenyl-beta-phenyl-3-quinolinethanol

Info

Publication number
DK2086940T3
DK2086940T3 DK07847697.5T DK07847697T DK2086940T3 DK 2086940 T3 DK2086940 T3 DK 2086940T3 DK 07847697 T DK07847697 T DK 07847697T DK 2086940 T3 DK2086940 T3 DK 2086940T3
Authority
DK
Denmark
Prior art keywords
alfa
beta
quinolinethanol
brom
naphthalenyl
Prior art date
Application number
DK07847697.5T
Other languages
English (en)
Inventor
Remoortere Peter Jozef Maria Van
Jean Francois Alexandre Lucas Hegyi
Wim Albert Alex Aelterman
Yolande Lydia Lang
Sigrid Carl Maria Stokbroekx
Carina Leys
Anne Faure
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37983588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2086940(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK2086940T3 publication Critical patent/DK2086940T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
DK07847697.5T 2006-12-05 2007-12-03 Fumaratsalt af (alfa- s, beta-r)-6-brom-alfa-[2-(dimethylamino)-ethyl]-2-methoxy-alfa-1-naphthalenyl-beta-phenyl-3-quinolinethanol DK2086940T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125443 2006-12-05
PCT/EP2007/063186 WO2008068231A1 (en) 2006-12-05 2007-12-03 Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

Publications (1)

Publication Number Publication Date
DK2086940T3 true DK2086940T3 (da) 2012-08-20

Family

ID=37983588

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07847697.5T DK2086940T3 (da) 2006-12-05 2007-12-03 Fumaratsalt af (alfa- s, beta-r)-6-brom-alfa-[2-(dimethylamino)-ethyl]-2-methoxy-alfa-1-naphthalenyl-beta-phenyl-3-quinolinethanol

Country Status (34)

Country Link
US (1) US8546428B2 (da)
EP (1) EP2086940B1 (da)
JP (2) JP2010511663A (da)
KR (1) KR101514700B1 (da)
CN (2) CN105012303A (da)
AP (1) AP2498A (da)
AR (1) AR064149A1 (da)
AU (1) AU2007328945B2 (da)
BR (1) BRPI0719693A2 (da)
CA (1) CA2668512C (da)
CL (1) CL2007003472A1 (da)
CY (1) CY1113594T1 (da)
DK (1) DK2086940T3 (da)
EA (1) EA017091B9 (da)
ES (1) ES2387923T3 (da)
HK (1) HK1214513A1 (da)
HR (1) HRP20120639T1 (da)
IL (1) IL199077A (da)
JO (1) JO2973B1 (da)
ME (1) ME01456B (da)
MX (1) MX2009005909A (da)
MY (1) MY148844A (da)
NO (1) NO342773B1 (da)
NZ (1) NZ576485A (da)
PE (1) PE20081350A1 (da)
PL (1) PL2086940T3 (da)
PT (1) PT2086940E (da)
RS (1) RS52408B (da)
SI (1) SI2086940T1 (da)
TW (1) TWI417098B (da)
UA (1) UA97813C2 (da)
UY (1) UY30762A1 (da)
WO (1) WO2008068231A1 (da)
ZA (1) ZA200903907B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CZ2014708A3 (cs) * 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
IL253626B1 (en) * 2015-01-27 2024-04-01 Janssen Pharmaceutica Nv dispersible preparations
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) * 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
US10196360B2 (en) 2015-10-20 2019-02-05 Zhejiang Hisun Pharmaceutical Co., Ltd. Crystal forms of bedaquiline fumarate and preparation methods therefor
AU2017298187B2 (en) * 2016-07-20 2019-11-14 Novartis Ag Aminopyridine derivatives and their use as selective ALK-2 inhibitors
CN106316943A (zh) * 2016-07-27 2017-01-11 重庆华邦制药有限公司 富马酸贝达喹啉晶型化合物的精制方法
JP2022516671A (ja) 2019-01-09 2022-03-01 ヤンセン ファーマシューティカ エヌ.ベー. 非結核性抗酸菌症の処置における組合せ
WO2020161743A1 (en) * 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
KR102303635B1 (ko) * 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
JP2023549605A (ja) 2020-11-12 2023-11-28 ヤンセン ファーマシューティカ エヌ.ベー. 非結核性マイコバクテリア疾患の治療におけるベダキリン、エタンブトール、及びマクロライドの組合せ
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
WO1998018326A1 (en) * 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
CA2219377A1 (en) * 1996-10-30 1998-04-30 Eli Lilly And Company Improvements in or relating to the prophylaxis of breast cancer
US6819464B2 (en) * 2002-06-19 2004-11-16 Seiko Epson Corporation Optical modulator, optical device and projector
EP1527050B1 (en) * 2002-07-25 2010-04-07 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
JO2524B1 (en) * 2004-05-28 2010-03-17 جانسن فارمسيتكا ان في Use of substituted quinoline derivatives to treat drug-resistant microbial diseases
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
EA009779B1 (ru) * 2004-12-24 2008-04-28 Янссен Фармацевтика Н.В. Лечение латентного туберкулёза

Also Published As

Publication number Publication date
BRPI0719693A2 (pt) 2013-12-24
UY30762A1 (es) 2008-07-03
NO20092535L (no) 2009-08-06
NZ576485A (en) 2012-01-12
EP2086940B1 (en) 2012-05-16
EA017091B1 (ru) 2012-09-28
TW200838527A (en) 2008-10-01
SI2086940T1 (sl) 2012-09-28
PL2086940T3 (pl) 2012-10-31
EA017091B9 (ru) 2014-10-30
AP2498A (en) 2012-10-19
PE20081350A1 (es) 2008-09-18
UA97813C2 (uk) 2012-03-26
JP2010511663A (ja) 2010-04-15
KR20090087020A (ko) 2009-08-14
CY1113594T1 (el) 2016-06-22
AU2007328945B2 (en) 2014-04-03
WO2008068231A1 (en) 2008-06-12
ME01456B (me) 2014-04-20
KR101514700B1 (ko) 2015-04-24
TWI417098B (zh) 2013-12-01
NO342773B1 (no) 2018-08-06
JO2973B1 (en) 2016-03-15
AR064149A1 (es) 2009-03-18
MY148844A (en) 2013-06-14
US8546428B2 (en) 2013-10-01
EP2086940A1 (en) 2009-08-12
RS52408B (en) 2013-02-28
AU2007328945A1 (en) 2008-06-12
CN101547904A (zh) 2009-09-30
JP2015028049A (ja) 2015-02-12
HK1214513A1 (zh) 2016-07-29
EA200970532A1 (ru) 2009-10-30
HRP20120639T1 (hr) 2012-08-31
MX2009005909A (es) 2009-06-16
AP2009004870A0 (en) 2009-06-30
CA2668512A1 (en) 2008-06-12
CN105012303A (zh) 2015-11-04
US20100028428A1 (en) 2010-02-04
CL2007003472A1 (es) 2008-08-22
PT2086940E (pt) 2012-08-09
ES2387923T3 (es) 2012-10-04
IL199077A (en) 2016-09-29
ZA200903907B (en) 2013-08-28
JP5894239B2 (ja) 2016-03-23
CA2668512C (en) 2015-03-24

Similar Documents

Publication Publication Date Title
DK2086940T3 (da) Fumaratsalt af (alfa- s, beta-r)-6-brom-alfa-[2-(dimethylamino)-ethyl]-2-methoxy-alfa-1-naphthalenyl-beta-phenyl-3-quinolinethanol
DK2101570T3 (da) Tannatsalt af rasagilin
BRPI0722082A2 (pt) Ligantes para imagiologia da inervação cardíaca
DE502008000295D1 (de) Nockenwelle
DE112007002915A5 (de) Verstelleinrichtung
DE502007002976D1 (de) Nockenwelle
FR2908035B1 (fr) Implant interepineux
BRPI0814314A2 (pt) Microbiocidas
ATE449068T1 (de) Neue mikrobiozide
DE502007001122D1 (de) Humeruskomponente
DK2114147T3 (da) Reduktion af bivirkninger af tramadol
SE0602723L (sv) Belagt skär
DE112007000221A5 (de) Abseilvorrichtung
BRPI0813781A2 (pt) microbiocidas
ATE523493T1 (de) 2-(1-oxo-1h-isochinolin-2-yl) acetamid-derivate
DK2054363T3 (da) Asymmetrisk hydrogenering af 1,1,1-trifluoracetone
DE502006005208D1 (de) Kochgefäss
DE602007002163D1 (de) Weichspülmittel
DE502006007220D1 (de) Nockenwelle
DK2089708T3 (da) Forudsigelige kræft-immunterapi parametre
DK2046745T3 (da) Fremgangsmåde til fremstilling af amorft lercanidipin-hydrochlorid
DE602007011413D1 (de) Phasenregelkreiselement
ITVI20060074A1 (it) Struttura di ancoraggio,particolarmente per radiatori
FI20065528A0 (fi) Moniresonanssiantenni
ITMI20060760A1 (it) Procedimento per il trattamento di tessuti